Remove Clinical Development Remove In-Vivo Remove Reagent Remove Research
article thumbnail

The evolution of assays for immuno-oncology research

Drug Discovery World

The first such research dates back to 1891, when William Coley attempted to inject heat-inactivated bacteria to treat osteosarcoma. This is an exciting field of cancer research which involves harnessing the body’s own immune system to target cancerous cells. This continues to be the standard of care.

article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

GSK has developed high-throughput mammalian and E. coli expression systems and is using high-throughput expression pipelines to screen constructs for optimal expression to generate protein and cellular reagents. DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Fortis Life Sciences leads the way in custom antibody discovery

Drug Discovery World

In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Moreover, custom antibodies are a key reagent in companion diagnostics for these novel therapeutics. This article is sponsored by Fortis Life Sciences.

article thumbnail

BioSpace Global Roundup, Oct. 15

The Pharma Data

AOP anticipates new opportunities in Austria as a hub for research and business. Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML.